News & Publications

News

Deals & Cases

Sobi acquires NovImmune’s Immunology Business in CHF 515 Mio. Deal

12 June 2019 – Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI) and NovImmune SA announced the transaction relating to the sale of the emapalumab business spun-off from NovImmune. The total consideration for the acquisition is CHF 515 mio. The transaction shall be completed during Q3 2019.

NovImmune SA is a privately held Swiss biopharmaceutical company with more than 140 employees operating from Geneva and Basel, Switzerland. The lead drug emapalumab is the first and only medicine approved in the US for primary HLH, a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. Sobi is an international biopharmaceutical company listed on Nasdaq Stockholm.

Walder Wyss has acted as legal counsel to NovImmune’s management team as sellers. The Walder Wyss team is being led by Alex Nikitine (Partner, Corporate/M&A, Capital Markets) and further included Dimitrios Berger (Associate, Corporate/M&A), Thomas Meister (Partner, Tax), Michael Isler (Partner, IP/IT), Janine Corti (Counsel, Tax), Christian Hagen (Associate, Corporate/M&A) and Daniel Donauer (Associate, Corporate/M&A).

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.